NEWS IS OUT
Geron Announces Presentations at American Society of Hematology Annual Meeting
MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the imetelstat program have been accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 3-6, 2016. The abstracts were published today on the ASH website at www.hematology.org.
Oral Presentation
One abstract containing non-clinical data on imetelstat was selected for oral presentation. These data extend previous preclinical work conducted in a patient-derived model of acute myeloid leukemia.
Title: The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML - a randomized trial in patient-derived xenografts (Abstract #578)
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Targeting Leukemia-Initiating Cells
Session Date: Monday, December 5, 2016
Presentation Time: 7:15 a.m. PT
Poster Presentations
Three abstracts related to imetelstat were selected for presentation as posters. One abstract investigates the potential impact of imetelstat on leukemia stem cells in a non-clinical model of chronic myeloid leukemia. The second abstract reports new data on telomere length dynamics from essential thrombocythemia patients providing further support that imetelstat treatment may suppress the neoplastic clones underlying the disease. The third abstract presents an analysis of treatment patterns and outcomes of patients with myelofibrosis from the United States medical claims databases that underscores the need for additional treatment options in that disease.
Title: Telomerase Inhibition with Imetelstat Eradicates ß-catenin Activated Blast Crisis Chronic Myeloid Leukemia Stem Cells (Abstract #3065)
Session Name: 632. Chronic Myeloid Leukemia: Therapy: Poster II
Session Date: Sunday, December 4, 2016
Session Time: 6:00 p.m. - 8:00 p.m. PT
Title: Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia (Abstract #1938)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Poster I
